The cost-effectiveness of subcutaneous semaglutide 2.4 mg in the management of people living with obesity and prediabetes in England
Semaglutide is a cost-effective treatment option for PwO and prediabetes in England based on the results of the STEP-10 trial.
Authors
- Mark Lamotte
- Matthew Capehorn (ORCID: https://orcid.org/0000-0002-8196-2505)
- Mafalda Ramos (ORCID: https://orcid.org/0000-0002-8472-3841)
- Francesco Fusco (ORCID: https://orcid.org/0000-0001-5515-3977)
- Sára Larsen (ORCID: https://orcid.org/0000-0002-3887-4948)
Institutions
- American Society of Safety Professionals (US)
- Novo Nordisk (Denmark) (DK)
- The Rotherham NHS Foundation Trust (GB)
- Institute for Disease Modeling (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1080/13696998.2025.2575692
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29